The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Moskvicheva L.I.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

High-intensity focused ultrasound therapy in the treatment of patients with desmoid fibromatosis

Authors:

Moskvicheva L.I.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2023;12(6): 68‑74

DOI: 10.17116/onkolog20231206168

Read: 1556 times

Download PDF (RU)
Contact the author
Table of contents

HIGH-INTENSITY FOCUSED ULTRASOUND THERAPY IN THE TREATMENT OF PATIENTS WITH DESMOID FIBROMATOSIS
HIGH-INTENSITY FOCUSED ULTRASOUND THERAPY IN THE TREATMENT OF PATIENTS WITH DESMOID FIBROMATOSIS

To cite this article:

Moskvicheva LI. High-intensity focused ultrasound therapy in the treatment of patients with desmoid fibromatosis. P.A. Herzen Journal of Oncology. 2023;12(6):68‑74. (In Russ.)
https://doi.org/10.17116/onkolog20231206168

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Use of HIFU therapy in combination with mono­chemotherapy in a patient with loca­lly adva­nced adenogenic pancreatic cancer and impaired functional status. P.A. Herzen Journal of Onco­logy. 2025;(3):83-88
Undi­fferentiated pleomorphic sarcoma asso­ciated with desmoid fibromatosis of soft tissues. P.A. Herzen Journal of Onco­logy. 2026;(1):43-46
Desmoid fibroma in abdo­minal surgery. Piro­gov Russian Journal of Surgery. 2025;(10):126-130
Abstract:

Desmoid fibromatosis remains a relatively rare tumor, which has led to significant challenges in its study. Despite its lack of metastatic potential, these tumors exhibit aggressive local destructive growth, low sensitivity to therapy, frequent recurrence, and a pronounced impact on the functional status of patients. Currently, the main treatment options for desmoid fibromatosis include resection surgery, radiation therapy, and systemic drug therapy. Increasingly, the possibilities of various physical destruction methods are being explored, one of which is high-intensity focused ultrasound therapy. This work presents modern data on the epidemiology, anatomy, and morphology of desmoid tumors, as well as a comprehensive description of the experiences of foreign researchers regarding the effectiveness and safety of high-intensity focused ultrasound therapy using various types of devices in patients with desmoid fibromatosis of various locations.

Keywords:

desmoid fibromatosis
aggressive fibromatosis
high-intensity focused ultrasound therapy
HIFU therapy
MRgHIFU
USgHIFU

Authors:

Moskvicheva L.I.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Received:

12.04.2023

Accepted:

02.05.2023

Close metadata

References:

  1. Martínez Trufero J, Pajares Bernad I, Torres Ramón I, Hernando Cubero J, Pazo Cid R. Desmoid-type fibromatosis: who, when, and how to treat. Curr Treat Options Oncol. 2017;18(5):29.  https://doi.org/10.1007/s11864-017-0474-0
  2. Kasper B. The EORTC QLQ-C30 summary score as a prognostic factor for survival of patients with cancer: a commentary. Oncologist. 2020;25(4):610-611.  https://doi.org/10.1634/theoncologist.2019-0749
  3. van Broekhoven DL, Grünhagen DJ, den Bakker MA, van Dalen T, Verhoef C. Time trends in the incidence and treatment of extra-abdominal and abdominal aggressive fibromatosis: a population-based study. Ann Surg Oncol. 2015;22(9):2817-2823. https://doi.org/10.1245/s10434-015-4632-y
  4. Li Destri G, Ferraro MJ, Calabrini M, Pennisi M. Magro G. Desmoid-type fibromatosis of the mesentery: report of a sporadic case with emphasis on differential diagnostic problems. Case Rep Med. 2014;2014:850180. https://doi.org/10.1155/2014/850180
  5. Desmoid Tumor Working Group. The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer. 2020;127:96-107.  https://doi.org/10.1016/j.ejca.2019.11.013
  6. Koskenvuo L, Ristimäki A, Lepistö A. Comparison of sporadic and FAP-associated desmoid-type fibromatoses. J Surg Oncol. 2017;116(6):716-721.  https://doi.org/10.1002/jso.24699
  7. Saito Y, Hinoi T, Ueno H, Kobayashi H, Konishi T, Ishida F, Yamaguchi T, Inoue Y, Kanemitsu Y, Tomita N, et al. Risk factors for the development of desmoid tumor after colectomy in patients with familial adenomatous polyposis: multicenter retrospective cohort study in Japan. Ann Surg Oncol. 2016;23(suppl 4):559-565.  https://doi.org/10.1245/s10434-016-5380-3
  8. Sanchez-Mete L, Ferraresi V, Caterino M, Martayan A, Terrenato I, Mannisi E, Stigliano V. Desmoid tumors characteristics, clinical management, active surveillance, and description of our FAP case series. J Clin Med. 2020;9(12):4012. https://doi.org/10.3390/jcm9124012
  9. De Marchis M, Tonelli F, Quaresmini D, Lovero D, Della-Morte D, Silvestris F, Guadagni F, Palmirotta R. Desmoid tumors in familial adenomatous polyposis. Anticancer Res. 2017;37(7):3357-3366. https://doi.org/10.21873/anticanres.11702
  10. Nieuwenhuis MH, Lefevre JH, Bülow S, Järvinen H, Bertario L, Kernéis S, Parc Y, Vasen HF. Family history, surgery, and APC mutation are risk factors for desmoid tumors in familial adenomatous polyposis: an international cohort study. Dis Colon Rectum. 2011;54(10):1229-1234. https://doi.org/10.1097/DCR.0b013e318227e4e8
  11. Ratan R, Roland CL, Bishop AJ. Desmoid fibromatosis: management in an era of increasing options. Curr Oncol Rep. 2021;23(4):41.  https://doi.org/10.1007/s11912-021-01026-w
  12. Garcia-Ortega DY, Martín-Tellez KS, Cuellar-Hubbe M, Martínez-Said H, Álvarez-Cano A, Brener-Chaoul M, Alegría-Baños JA, Martínez-Tlahuel JL. Desmoid-type fibromatosis. Cancers (Basel). 2020;12(7):1851. https://doi.org/10.3390/cancers12071851
  13. Cojocaru E, Gennatas S, Thway K, Fisher C, Smrke A, Strauss D, Hayes A, Smith M, Jones RL, Benson C, McVeigh TP. Approach to screening for Familial Adenomatous Polyposis (FAP) in a cohort of 226 patients with Desmoid-type Fibromatosis (DF): experience of a specialist center in the UK. Fam Cancer. 2022;21(1):69-74.  https://doi.org/10.1007/s10689-021-00230-8
  14. Slowik V, Attard T, Dai H, Shah R, Septer S. Desmoid tumors complicating familial adenomatous polyposis: a meta-analysis mutation spectrum of affected individuals. BMC Gastroenterol. 2015;15:84.  https://doi.org/10.1186/s12876-015-0306-2
  15. Crago AM, Chmielecki J, Rosenberg M, O’Connor R, Byrne C, Wilder FG, Thorn K, Agius P, Kuk D, Socci ND, et al. Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis. Genes Chromosomes Cancer. 2015;54(10):606-615.  https://doi.org/10.1002/gcc.22272
  16. Ophir G, Sivan S, Hana S, Guy R, Nathan G, Naomi FI, Joseph K, Ido W, Ofer M, Yael G, et al. Abdominal desmoid: course, severe outcomes, and unique genetic background in a large local series. Cancers (Basel). 2021;13(15):3673. https://doi.org/10.3390/cancers13153673
  17. Kasper B, Raut CP, Gronchi A. Desmoid tumors: to treat or not to treat, That is the question. Cancer. 2020;126(24):5213-5221. https://doi.org/10.1002/cncr.33233
  18. Skubitz KM. Biology and treatment of aggressive fibromatosis or desmoid tumor. Mayo Clin Proc. 2017;92(6):947-964.  https://doi.org/10.1016/j.mayocp.2017.02.012
  19. Kasper B, Baumgarten C, Garcia J, Bonvalot S, Haas R, Haller F, Hohenberger P, Penel N, Messiou C, van der Graaf WT, et al. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). Ann Oncol. 2017;28(10):2399-2408. https://doi.org/10.1093/annonc/mdx323
  20. Penel N, Le Cesne A, Bonvalot S, Giraud A, Bompas E, Rios M, Salas S, Isambert N, Boudou-Rouquette P, Honore C, et al. Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: a nationwide prospective cohort from the French Sarcoma Group. Eur J Cancer. 2017;83:125-131.  https://doi.org/10.1016/j.ejca.2017.06.017
  21. Choi SH, Yoon HI, Kim SH, Kim SK, Shin KH, Suh CO. Optimal radiotherapy strategy for primary or recurrent fibromatosis and long-term results. PLoS One. 2018;13(5):e0198134. https://doi.org/10.1371/journal.pone.0198134
  22. Janssen ML, van Broekhoven DL, Cates JM, Bramer WM, Nuyttens JJ, Gronchi A, Salas S, Bonvalot S, Grünhagen DJ, Verhoef C. Meta-analysis of the influence of surgical margin and adjuvant radiotherapy on local recurrence after resection of sporadic desmoid-type fibromatosis. Br J Surg. 2017;104(4):347-357.  https://doi.org/10.1002/bjs.10477
  23. Bishop AJ, Zarzour MA, Ratan R, Torres KE, Feig BW, Wang WL, Lazar AJ, Moon BS, Roland CL, Guadagnolo BA. Long-term outcomes for patients with desmoid fibromatosis treated with radiation therapy: a 10-year update and re-evaluation of the role of radiation therapy for younger patients. Int J Radiat Oncol Biol Phys. 2019;103(5):1167-1174. https://doi.org/10.1016/j.ijrobp.2018.12.012
  24. Bishop AJ, Landry JP, Roland CL, Ratan R, Feig BW, Moon BS, Zarzour MA, Wang WL, Lazar AJ, Lewis VO, et al. Certain risk factors for patients with desmoid tumors warrant reconsideration of local therapy strategies. Cancer. 2020;126(14):3265-3273. https://doi.org/10.1002/cncr.32921
  25. Gronchi A, Colombo C, Le Péchoux C, Dei Tos AP, Le Cesne A, Marrari A, Penel N, Grignani G, Blay JY, Casali PG, et al. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm — a position paper from the Italian and the French Sarcoma Group. Ann Oncol. 2014;25(3):578-583.  https://doi.org/10.1093/annonc/mdt485
  26. Bolotina LV, Novikova OV, Prokof’eva EA. Role of chemotherapy in the treatment of aggressive fibromatosis. P.A. Herzen Journal of Oncology. 2012;1(3):72-76. (In Russ.).
  27. Palassini E, Frezza AM, Mariani L, Lalli L, Colombo C, Fiore M, Messina A, Casale A, Morosi C, Collini P, et al. Long-term efficacy of methotrexate plus vinblastine/vinorelbine in a large series of patients affected by desmoid-type fibromatosis. Cancer J. 2017;23(2):86-91.  https://doi.org/10.1097/PPO.0000000000000254
  28. Chugh R, Wathen JK, Patel SR, Maki RG, Meyers PA, Schuetze SM, Priebat DA, Thomas DG, Jacobson JA, Samuels BL, et al.; Sarcoma Alliance for Research through Collaboration (SARC). Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res. 2010;16(19):4884-4891. https://doi.org/10.1158/1078-0432.CCR-10-1177
  29. Toulmonde M, Pulido M, Ray-Coquard I, Andre T, Isambert N, Chevreau C, Penel N, Bompas E, Saada E, Bertucci F, et al. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol. 2019;20(9):1263-1272. https://doi.org/10.1016/S1470-2045(19)30276-1
  30. Kummar S, O’Sullivan Coyne G, Do KT, Turkbey B, Meltzer PS, Polley E, Choyke PL, Meehan R, Vilimas R, Horneffer Y, et al. Clinical activity of the γ-secretase inhibitor PF-03084014 in adults with desmoid tumors (aggressive fibromatosis). J Clin Oncol. 2017;35(14):1561-1569. https://doi.org/10.1200/JCO.2016.71.1994
  31. Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA, Gupta AA, Milhem MM, Conry RM, Movva S, et al. Sorafenib for advanced and refractory desmoid tumors. N Engl J Med. 2018;379(25):2417-2428. https://doi.org/10.1056/NEJMoa1805052
  32. Testa S, Bui NQ, Charville GW, Avedian RS, Steffner R, Ghanouni P, Mohler DG, Ganjoo KN. Management of patients with newly diagnosed desmoid tumors in a first-line setting. Cancers (Basel). 2022;14(16):3907. https://doi.org/10.3390/cancers14163907
  33. Mikhael R, Smith M, Tzanis D, Watson S, Miah AB, Bonvalot S. Desmoid tumors: who, when and how to treat? Curr Opin Oncol. 2022;34(4):335-341.  https://doi.org/10.1097/CCO.0000000000000854
  34. Moskvicheva LI, Sidorov DV, Lozhkin MV, Petrov LO, Zabelin MV. Modern methods of ablation of malignant tumors of the liver. Research and Practical Medicine Journal. 2018;5(4):58-71. (In Russ.). https://doi.org/10.17709/2409-2231-2018-5-4-6
  35. Zhou MY, Bui NQ, Charville GW, Ghanouni P, Ganjoo KN. Current management and recent progress in desmoid tumors. Cancer Treat Res Commun. 2022;31:100562. https://doi.org/10.1016/j.ctarc.2022.100562
  36. Izadifar Z, Izadifar Z, Chapman D, Babyn P. An introduction to high intensity focused ultrasound: systematic review on principles, devices, and clinical applications. J Clin Med. 2020;9(2):460.  https://doi.org/10.3390/jcm9020460
  37. Moskvicheva LI. High-intensity focused ultrasonic ablation of breast cancer. Research and Practical Medicine Journal. 2018;5(3):67-76. (In Russ.). https://doi.org/10.17709/2409-2231-2018-5-3-6
  38. Siedek F, Yeo SY, Heijman E, Grinstein O, Bratke G, Heneweer C, Puesken M, Persigehl T, Maintz D, Grüll H. Magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU): technical background and overview of current clinical applications (Part 1). Rofo. 2019;191(6):522-530.  https://doi.org/10.1055/a-0817-5645
  39. Elhelf IAS, Albahar H, Shah U, Oto A, Cressman E, Almekkawy M. High intensity focused ultrasound: the fundamentals, clinical applications and research trends. Diagn Interv Imaging. 2018;99(6):349-359.  https://doi.org/10.1016/j.diii.2018.03.001
  40. Bolotina LV, Moskvicheva LI, Kornietskaya AL, Sidorov DV, Grishin NA, Lozhkin MV, Kaprin AD. Preliminary evaluation of the effectiveness of HIFU-therapy in patients with pancreatic cancer. Siberian Journal of Oncology. 2021;20(3):18-27. (In Russ.). https://doi.org/10.21294/1814-4861-2021-20-3-18-27
  41. Moskvicheva LI. Application of HIFU therapy in oncology (2000-2021). P.A. Herzen Journal of Oncology. 2022;11(1):64-74. (In Russ.). https://doi.org/10.17116/onkolog20221101164
  42. Wang Y, Wang W, Tang J. Ultrasound-guided high intensity focused ultrasound treatment for extra-abdominal desmoid tumours: preliminary results. Int J Hyperthermia. 2011;27(7):648-653.  https://doi.org/10.3109/02656736.2011.597047
  43. Zhao WP, Han ZY, Zhang J, Yu XL, Cheng ZG, Zhou X, Liang P. Early experience: high-intensity focused ultrasound treatment for intra-abdominal aggressive fibromatosis of failure in surgery. Br J Radiol. 2016;89(1062):20151026. https://doi.org/10.1259/bjr.20151026
  44. Zhang R, Chen JY, Zhang L, Li KQ, Xiao ZB, Mo SJ, Chen L, Chen WZ. The safety and ablation efficacy of ultrasound-guided high-intensity focused ultrasound ablation for desmoid tumors. Int J Hyperthermia. 2021;38(2):89-95.  https://doi.org/10.1080/02656736.2021.1894359
  45. Zhong X, Hu X, Zhao P, Wang Y, Fang XF, Shen J, Shen H, Yuan Y. The efficacy of low-power cumulative high-intensity focused ultrasound treatment for recurrent desmoid tumor. Cancer Med. 2022;11(10):2079-2084. https://doi.org/10.1002/cam4.4573
  46. Yang Y, Zhang J, Pan Y. Management of unresectable and recurrent intra-abdominal desmoid tumors treated with ultrasound-guided high-intensity focused ultrasound: a retrospective single-center study. Medicine (Baltimore). 2022;101(34):e30201. https://doi.org/10.1097/MD.0000000000030201
  47. Ghanouni P, Dobrotwir A, Bazzocchi A, Bucknor M, Bitton R, Rosenberg J, Telischak K, Busacca M, Ferrari S, Albisinni U, et al. Magnetic resonance-guided focused ultrasound treatment of extra-abdominal desmoid tumors: a retrospective multicenter study. Eur Radiol. 2017;27(2):732-740.  https://doi.org/10.1007/s00330-016-4376-5
  48. Najafi A, Fuchs B, Binkert CA. Mid-term results of MR-guided high-intensity focused ultrasound treatment for relapsing superficial desmoids. Int J Hyperthermia. 2019;36(1):538-542.  https://doi.org/10.1080/02656736.2019.1608376
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.